pegylated interferon-alpha-2a

DRUG2 trials

Sponsors

University Hospital Tuebingen, ANRS, Emerging Infectious Diseases

Conditions

AgHbs NegativationChronic Hepatitis BMelanoma

Phase 3

Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB

CompletedNCT00204529

University Hospital TuebingenMelanoma

Start: 2004-10-31End: 2016-12-31Updated: 2017-05-03

A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B

ANRS, Emerging Infectious DiseasesAgHbs Negativation, Chronic Hepatitis B

Start: 2011-01-31End: 2015-06-30Updated: 2013-03-29

Related Papers

Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.

2017-01-2083 citations

Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial.

2016-06-1022 citations

Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon alfa-2a (IFN) in patients with malignant melanoma in stages IIa(T3a): IIIb (AJCC 2002)—Decog-trial.

Journal of Clinical Oncology2014-05-202 citations